Key Catalyst In August For Mologen As IMPALA Phase III Colorectal Cancer Reports

17 Jul 2019

• By Sten Stovall

Mologen CEO says next month’s pivotal trial topline readout on its lead asset lefitolimod will be important for the German-based immunotherapy pioneer of DNA-based TLR9 agonists.

DNA strand — Mologen's immunotherapy focus is on developing DNA-based TLR9 agonists • Source: Shutterstock

Key Catalyst In August For Mologen As IMPALA Phase III Colorectal Cancer Reports

More from Clinical Trials

More from R&D